Medigen Vaccine Biologics Corporation (TPEX:6547)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
48.35
-0.95 (-1.93%)
Apr 2, 2025, 1:30 PM CST
-7.02%
Market Cap 15.86B
Revenue (ttm) 605.64M
Net Income (ttm) -80.47M
Shares Out 328.73M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE 37.40
Dividend n/a
Ex-Dividend Date n/a
Volume 1,598,298
Average Volume 2,555,432
Open 49.95
Previous Close 49.30
Day's Range 48.20 - 50.00
52-Week Range 33.70 - 57.00
Beta 1.06
RSI 40.38
Earnings Date Mar 18, 2025

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respirat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 103
Stock Exchange Taipei Exchange
Ticker Symbol 6547
Full Company Profile

Financial Performance

In 2024, Medigen Vaccine Biologics's revenue was 605.64 million, an increase of 55.44% compared to the previous year's 389.62 million. Losses were -80.47 million, -93.06% less than in 2023.

Financial Statements

News

There is no news available yet.